Corporate Responsibility
Corporate Responsibility

Patient Assistance Program (PAP)

The Takeda Patient Assistance Program (PAP) provides patients with access to medications for a variety of conditions. To qualify for free Takeda medication, patients must meet the following conditions:

  • Resident of the United States. You must live in the United States and for some assistance programs must provide proof of residency with either a Social Security Number, Green Card Number or Visa Number.
  • • A total household income less than 300% of the Your yearly household income includes all money that comes into your household. If you are married and live with your spouse, you must include both of your incomes. You must also include income earned by dependents living with you. Federal Poverty Level
  • • Patient must have a valid prescription for a Takeda medicine (see the list below)
  • • No prescription coverage through private or government programs
  • • Patients who are eligible for or enrolled in Medicare Part D may still apply, and they may be eligible to receive free Takeda medicines through the end of the calendar year

Takeda Medicines Available through the Patient Assistance Program


Brand Name Generic Name
ACTOS® 15 mg tablet pioglitazone HCl
ACTOS® 30 mg tablet pioglitazone HCl
ACTOS® 45 mg tablet pioglitazone HCl
ACTOplus met® 15 mg/500 mg tablet pioglitazone HCl + metformin HCl
ACTOplus met® 15 mg/850 mg tablet pioglitazone HCl + metformin HCl
ACTOplus met® XR 15 mg/1000 mg tablet pioglitazone HCl + metformin HCl XR
ACTOplus met® XR 30 mg/1000 mg tablet pioglitazone HCl + metformin HCl XR
AMITIZA® 8 mcg capsule lubiprostone
AMITIZA® 24 mcg capsule lubiprostone
DEXILANTTM 30 mg capsule dexlansoprazole
DEXILANTTM 60 mg capsule dexlansoprazole
duetact® 30 mg/2 mg tablet pioglitazone HCl and glimepiride
duetact® 30 mg/4 mg tablet pioglitazone HCl and glimepiride
Rozerem® 8 mg tablet ramelteon
ULORIC® 40 mg tablet febuxostat
ULORIC® 80 mg tablet febuxostat

ACTOS, ACTOplus met, ACTOplus met XR and Duetact are trademarks of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

ROZEREM is a trademark of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

DEXILANT is a trademark of Takeda Pharmaceuticals North America, Inc. and used under license by Takeda Pharmaceuticals America, Inc.

AMITIZA is a trademark of Sucampo Pharmaceuticals, Inc. registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

ULORIC is a trademark of Teijin Pharma Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

This program, as well as all Takeda Pharmaceuticals America, Inc. programs, can be discontinued or changed at any time without notice at the discretion of Takeda Pharmaceuticals America, Inc.

Patient Assistance Program

In 2009, the Takeda Patient Assistance Program provided over 85,000 patients with 218,000 prescriptions valued at $118 million. It’s all part of Takeda’s commitment to help improve lives with better healthcare.





Page Top